Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
February 03 2021 - 12:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of February 2021
Commission File Number: 333-231839
CHINA SXT PHARMACEUTICALS, INC.
(Translation of registrant’s name
into English)
178 Taidong Rd North, Taizhou
Jiangsu, China
(Address of principal executive office)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Note: Regulation S-T Rule 101(b)(1) only
permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private
issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s
securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed
to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission
or other Commission filing on EDGAR.
Appointment of Certain Officer
Appointment of New CFO
On February 1, 2021, Mr. Wang Lee was appointed
as the Chief Financial Officer (“CFO”) of the Company, effective immediately. Mr. Feng Zhou ceased to serve as the
interim CFO of the Company simultaneously.
Prior to joining the Company, Mr. Lee acted
as the Securities Operation Director at Wanda Sports Group Co., Ltd. (NASDAQ: WSG) from January 2019 and April 2020. He joined
Wanda Sports from Secoo Holding Limited (NASDAQ: SECO) , where he served as the Finance Reporting Director from May 2017 and December
2019. Mr. Lee earned his Bachelor of Business Administration Degree from University of Houston in 2001 and is a certified public
accountant in Texas. Mr. Lee’s extensive experience in funding, merger and acquisition will be critical to the future business
expansion for the Company. Mr. Lee has no family relationship with any directors or executive officers of the Company.
A copy of the employment agreement with Mr. Wang Lee is attached
hereto as exhibit 10.1.
SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENT
This Current Report contains forward-looking
statements. All statements contained in this Current Report other than statements of historical fact are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “seek” and similar expressions are intended to identify forward-looking
statements. We have based these forward-looking statements largely on our current expectations and projections about future events
and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term
business operations and objectives, and financial needs.
These forward-looking statements are subject
to a number of risks, uncertainties and assumptions, including, but not limited to, the following: the effects of the COVID-19
outbreak, including its impact on the demand for our products; the duration of the COVID-19 outbreak and severity of such
outbreak in regions where we operate; the pace of recovery following the COVID-19 outbreak; our ability to implement
cost containment and business recovery strategies; the adverse effects of the COVID-19 outbreak on our business or the market
price of our ordinary shares, the Company's goals and strategies; the Company's future business development; product and service
demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing;
government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related
to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission.
In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Current Report may not occur
and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking
statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be
achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot
guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, we undertake
no duty to update any of these forward-looking statements after the date of this Current Report or to conform these statements
to actual results or revised expectations.
Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
CHINA SXT PHARMACEUTICAL, INC.
|
|
|
|
|
By:
|
/s/ Feng Zhou
|
|
|
Feng Zhou
|
|
|
Chief Executive Officer
|
Date: February 3, 2021
3
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Jan 2025 to Feb 2025
China SXT Pharmaceuticals (NASDAQ:SXTC)
Historical Stock Chart
From Feb 2024 to Feb 2025